Sarah Goldberg, MD, MPH, details how clinicians can choose among frontline regimens, act on resistance mechanisms, and incorporate ADCs and newer agents across the spectrum of EGFR-mutated NSCLC.
Commentary|Articles|August 8, 2025
NSCLC Experts Highlight Clinical Trials to Watch in 2025
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Lung cancer experts share upcoming, potentially practice-informing clinical trials that are expected to read out in the second half of 2025.
Advertisement
Advertisement
The non–small cell lung cancer (NSCLC) treatment paradigm is rapidly evolving, with multiple clinical trials poised to reshape standards of care for several patient subgroups. OncLive® asked leading lung cancer experts to share the research and readouts they’re most highly anticipating over the next few months. We heard from:
Related to this article
The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.
The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement